OncoVista Innovative Therapies, Inc.
OVIT · OTC
12/31/2014 | 12/31/2013 | 12/31/2012 | 12/31/2011 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.06 | 0.09 | 0.41 |
| FCF Yield | -17.89% | -43.17% | -55.56% | -21.61% |
| EV / EBITDA | -0.59 | -0.68 | -1.41 | -2.50 |
| Quality | ||||
| ROIC | 53.54% | 48.79% | 117.99% | -5,038.97% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.09 | 0.32 | 0.95 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 50.22% | 69.96% | 3.60% | -190.43% |
| Safety | ||||
| Net Debt / EBITDA | -0.08 | 0.03 | 0.32 | 0.89 |
| Interest Coverage | -305.91 | -10,014.41 | -289.37 | -91.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |